

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT NEW SPECIFICATIONS FILLER OF PLLA OF SIHUAN PHARMACEUTICAL APPROVED FOR MARKET BY NMPA

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that six new specifications of the polylactic acid facial filler (market abbreviation “**PLLA filler**”) independently developed by Meiyuan Space Biotechnology (Jilin) Co., Ltd. (the “**Meiyuan Space**”), a subsidiary of the Group, have been approved by the National Medical Products Administration of China (the “**NMPA**”). This is another important development after the product was first approved, further improving the Company’s market layout in the field of regenerative medical aesthetic products.

As the only domestic enterprise that holds both compliant “PCL filler” and “PLLA filler” regenerative filling products, as well as botulinum toxin, skin boosters and radiofrequency microneedling, all of which are heavyweight Class III medical devices, Sihuan Pharmaceutical’s PLLA filler achieves the dual effect of “instant filling + long-term regeneration” with the core ingredient of Poly L-lactic acid (PLLA) microspheres. Its unique patented technology ensures that the microsphere morphology is regular, the particle size is uniform, and the safety and clinical efficacy are excellent. Most patients can maintain effective effects for one year after injection. Prior to this specification expansion, the product has already been approved in three specifications, including 45 mg/bottle, 75 mg/bottle and 150 mg/bottle, which are suitable for different needs such as preventive management, combination therapy, and comprehensive rejuvenation; The six newly approved specifications, including 60 mg/bottle, 80 mg/bottle, 100 mg/bottle, 110 mg/bottle, 120 mg/bottle, 130 mg/bottle, will further enrich the product selection spectrum.

The value and significance of this specification expansion are as follows:

1. Precise matching of diverse anti-aging needs: The new specifications fill the dosage gap between existing specifications, achieving full scene coverage from mild early aging to moderate to severe aging. Whether it is slight dullness improvement in delicate areas or moderate fullness demand in facial contours, personalized treatment can be achieved through precise dosage selection, meeting the specific needs of different age groups.
2. Optimizing clinical operation flexibility: Based on the product's ability to quickly dissolve within 1 minute, multiple specifications are available for doctors to flexibly adjust dilution concentration and injection dose according to the injection site and treatment depths, reducing the complexity of combination therapy and improving treatment efficiency and safety.
3. Strengthening market competition barriers: Against the backdrop of PLLA filler's market sustained growth in the global and intense domestic competition, the multi specification layout further consolidates the differentiated advantages of Sihuan Pharmaceutical in the field of regenerative medical aesthetic, forming a synergistic effect with its products such as "PCL filler" and "Double Wave RF", and improving the product matrix of the medical aesthetic category.
4. Promoting the refined development of the industry: This specification expansion responds to the trend of the medical aesthetic industry from "standardized treatment" to "personalized solutions". Through dose segmentation, it guides the industry to focus on individual differences of patients and provides industry reference for the specification design of regenerative medical aesthetic products, helping the industry upgrade towards high-quality and refined direction.

Sihuan Pharmaceutical will rely on a strong sales channel network covering over 7,000 medical institutions to quickly promote the market landing of new specifications, continue to empower medical aesthetic product innovation with pharmaceutical companies' research and development genes, provide consumers with safer, more accurate, and diversified anti-aging solutions, and promote the medical aesthetic sector of the Group to enter a new stage of large-scale growth.

ABOUT MEIYAN SPACE

Meiyan Space is a new type of "one-stop" medical aesthetic platform incubated by Sihuan Pharmaceutical, through the globalization layout, comprehensive and professional medical aesthetic product matrix, product research and development, registration, production and sales of an integrated structure, is dedicated to building a leading company featuring a full medical aesthetics product matrix in China by leveraging the rigour and innovation of pharmaceutical companies. Meiyan Space continues to build a complete product matrix covering the whole life cycle needs of beauty lovers through the dual-engine drive of "self-research + BD", with more than 60 products in the pipeline, covering the basic categories of light medical aesthetic,

including fillers, contouring, support, optoelectronic equipment and skin management. Meanwhile, Meiyen Space has strong independent research and development and technology transfer strength, the professional BD team and R&D team in China and abroad can quickly promote the research and development and launching of medical aesthetic products. At present, Meiyen Space has established three production bases globally, with a perfect quality management system and effective risk management for the whole life cycle of products. Its experienced medical aesthetic sales team, nationwide sales network and well developed system can quickly promote the sales of products. Most of the sales team members of Meiyen Space come from multinational medical aesthetic and pharmaceutical enterprises, with rich experience in the sales of medical aesthetic products, and work closely with dozens of agents, the sales network has covered more than 370 cities and more than 7,000 medical aesthetic institutions.

ABOUT SIHUAN PHARMACEUTICAL

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group’s latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, medical equipment, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 16 January 2026

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.